高度免疫グロブリン製剤の世界市場レポート2025-2031

QY Research > レポート一覧 > 薬品及びサプリメント > 高度免疫グロブリン製剤の世界市場レポート2025-2031

英文タイトル： Global Hyperimmune Globulin Injection Market Outlook, In‑Depth Analysis & Forecast to 2031

レポートID：1572030
発表時期：2025-10-03
訪問回数：17
ページ数：155
レポート形式：PDF
レポート言語：英語、日本語
グラフ数：156
レポートカテゴリ：薬品及びサプリメント

販売価格（消費税別）

個人版
詳細
マルチユーザー版
詳細
企業版
詳細

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.70円。
※米ドル表示価格+10％消費税。

英語版

日本語版

英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.70円。
※米ドル表示価格+10％消費税。

お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合，注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。但し、日本語版が必要な場合は、受注後8～10営業日となります。お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

概要

本報告書は、高度免疫グロブリン製剤の世界市場について、容量、生産量、収益、価格の概要を紹介します。2021年から2025年までの過去の市場収益/売上データ、2026年の予測データ、ならびに2032年までのCAGR（年平均成長率）予測を含む、世界市場動向の分析を提供します。本レポートは、メーカー、地域、製品種類、およびエンドユーザー産業の観点から、世界と主要地域の市場現状と将来性を研究したものです。世界と主要地域のトップメーカーを分析し、製品タイプおよびアプリケーション/エンドユーザー産業別に高度免疫グロブリン製剤市場を分類しています。

本レポートでは、世界の高度免疫グロブリン製剤市場の主要参加企業として、企業概要、販売数量、収益、価格、粗利益率、製品ポートフォリオ、地理的位置、主要な事業展開を以下のパラメータに基づいて紹介します。
本レポートは高度免疫グロブリン製剤の主要生産者を調査するとともに、主要地域や国の消費状況も提供します。高度免疫グロブリン製剤の主要地域／国における将来の市場ポテンシャルを重点的に分析し、それに基づき、異なるセグメントおよびサブセグメントにおける市場の将来動向を予測しております。アメリカ、カナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、その他の国々について、各国データおよび市場価値分析を提供しております。
2021年から2032年までの期間について、タイプ別および用途別の売上高、収益、価格に基づくセグメントデータを分析します。

本研究に含まれる主な企業は以下の通りです：
CSL Behring
Grifols
Biotest
Kedrion
Emergent
Kamada
CNBG
Hualan Bio
Shanghai RAAS
CBPO
Sichuan Yuanda Shuyang
ADMA Biologics

タイプ別市場セグメント：
Hepatitis B Immuneglobulins
Rabies Immuneglobulins
Tetanus Toxin Immuneglobulins
Rho(D) Immune Globulin
Cytomegalovirus Immune Globulin
Varicella-Zoster Immune Globulin
Others

用途別市場セグメント：
Government Institution
Private Sector
Others

地域別の市場セグメント：
北米
アジア太平洋
欧州
中南米
中東・アフリカ

本レポートの詳細内容：
世界の高度免疫グロブリン製剤市場の現状と将来展望を包括的に分析し、グローバル主要地域における開発動向の綿密な調査を通じて、企業様に包括的な市場分析を提示します。市場の全体像を把握するため、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいて高度免疫グロブリン製剤市場を細分化しています。この分類と用途分析により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2021年から2026年までの実績と2032年までの予測として、メーカー別、地域別（地域レベル、国レベル）の高度免疫グロブリン製剤生産量、成長率、市場シェアを調査しています。
二. 消費面では、高度免疫グロブリン製剤の売上高について、地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2021年から2026年まで、および2032年までの予測を対象とします。
三. 主要メーカーの高度免疫グロブリン製剤売上高、収益、市場シェア、業界ランキングについて、2021年から2026年までのデータに焦点を当てています。世界の高度免疫グロブリン製剤市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づく競争状況と市場ポジショニングの分析を行います。
四. 本高度免疫グロブリン製剤レポートは、関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立案するのに役立つ洞察を提供することを目的としています。売上高、成長動向、生産技術、用途、エンドユーザー産業に関する市場規模の詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。
章節目次：
第1章：高度免疫グロブリン製剤レポートの範囲、市場セグメント（タイプ別、用途別など）ごとの市場規模、将来の発展可能性などをまとめたエグゼクティブサマリーをご紹介いたします。これにより、市場の最新状況を包括的に把握し、短期・中期・長期（2021-2032年）にわたる発展の見通しを把握いただけます。
第2章：高度免疫グロブリン製剤の世界および主要生産者（地域／国別）の生産量／アウトプットについて分析します。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています（2021年～2032年）
第3章：高度免疫グロブリン製剤の現在の市場状況を提示し、2032年までの世界的な収益・販売・生産を予測するとともに、消費量の多い地域と新興市場の成長要因を特定します（2021年～2032年）
第4章：高度免疫グロブリン製剤メーカーの競争状況、価格、売上高、収益、市場シェア、業界ランキング、最新の開発計画、合併・買収情報など詳細に分析します（2021年～2026年）
第5章：高度免疫グロブリン製剤の下流市場機会を特定し、用途別販売量・収益・価格設定を評価するとともに新興ユースケースを明らかにし、地域別・用途別の主要顧客をプロファイリングします
第6章：高度免疫グロブリン製剤のグローバル生産能力、稼働率、市場シェア（2021-2032年）をマッピングし、効率的拠点を特定するとともに規制や貿易政策の影響とボトルネックを解明します
第7章：北米における高度免疫グロブリン製剤市場をアプリケーション別・国別売上高・収益で分析し、主要メーカーをプロファイリングしつつ成長要因と障壁を評価します
第8章：欧州における高度免疫グロブリン製剤市場をアプリケーション別・メーカー別に地域別売上高・収益・市場分析を行い、成長要因と障壁を明示します
第9章：アジア太平洋地域の高度免疫グロブリン製剤市場を用途別・地域/国別の売上高と収益で定量化し、主要メーカーをプロファイリングするとともに高成長潜在地域を明らかにします
第10章：中南米における高度免疫グロブリン製剤市場を用途別・国別売上高と収益で測定し、主要メーカーをプロファイリングするとともに投資機会と課題を特定します
第11章：中東・アフリカ地域の高度免疫グロブリン製剤市場を用途別・国別に評価し、主要メーカーをプロファイリングするとともに投資見通しと市場障壁を概説します
第12章：高度免疫グロブリン製剤の主要メーカーの概要を提供し、製品説明、売上高、収益、価格、粗利益率、最近の事業拡大などの情報を整理するとともに、SWOT分析および戦略動向分析を行います
第13章：高度免疫グロブリン製剤のサプライチェーンを分析し、上流の原材料・供給業者、製造拠点と技術、コスト要因を明らかにします
第14章：高度免疫グロブリン製剤の市場動向、最新動向、推進要因と制約要因、業界内のメーカーが直面する課題とリスク、関連する業界政策の分析を紹介します
第15章：レポートの要点と結論
第16章：付録

Description

The global Hyperimmune Globulin Injection market is projected to grow from US$ 2207 million in 2024 to US$ 3391 million by 2031, at a CAGR of 6.4% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Hyperimmune Globulin is a highly concentrated immunoglobulin containing high levels of specific antibodies used for passive immunotherapy. It is usually extracted from the plasma of recovered patients who have been infected with a specific pathogen, so these people have produced high levels of antibodies against the pathogen.

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.

Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Hyperimmune Globulin Injection market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
CSL Behring
Grifols
Biotest
Kedrion
Emergent
Kamada
CNBG
Hualan Bio
Shanghai RAAS
CBPO
Sichuan Yuanda Shuyang
ADMA Biologics

Segment by Type
Hepatitis B Immuneglobulins
Rabies Immuneglobulins
Tetanus Toxin Immuneglobulins
Rho(D) Immune Globulin
Cytomegalovirus Immune Globulin
Varicella-Zoster Immune Globulin
Others

Segment by Application
Government Institution
Private Sector
Others

Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina

Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa

Chapter Outline
Chapter 1: Defines the Hyperimmune Globulin Injection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

Table of Contents

1 Study Coverage
1.1 Introduction to Hyperimmune Globulin Injection: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Hyperimmune Globulin Injection Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Hepatitis B Immuneglobulins
1.2.3 Rabies Immuneglobulins
1.2.4 Tetanus Toxin Immuneglobulins
1.2.5 Rho(D) Immune Globulin
1.2.6 Cytomegalovirus Immune Globulin
1.2.7 Varicella-Zoster Immune Globulin
1.2.8 Others
1.3 Market Segmentation by Application
1.3.1 Global Hyperimmune Globulin Injection Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Government Institution
1.3.3 Private Sector
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 Executive Summary
2.1 Global Hyperimmune Globulin Injection Revenue Estimates and Forecasts 2020-2031
2.2 Global Hyperimmune Globulin Injection Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Hyperimmune Globulin Injection Sales Estimates and Forecasts 2020-2031
2.4 Global Hyperimmune Globulin Injection Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers
3.1 Global Hyperimmune Globulin Injection Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Hyperimmune Globulin Injection Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Hepatitis B Immuneglobulins Market Size by Manufacturers
3.5.2 Rabies Immuneglobulins Market Size by Manufacturers
3.5.3 Tetanus Toxin Immuneglobulins Market Size by Manufacturers
3.5.4 Rho(D) Immune Globulin Market Size by Manufacturers
3.5.5 Cytomegalovirus Immune Globulin Market Size by Manufacturers
3.5.6 Varicella-Zoster Immune Globulin Market Size by Manufacturers
3.5.7 Others Market Size by Manufacturers
3.6 Global Hyperimmune Globulin Injection Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis
4.1 Global Hyperimmune Globulin Injection Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Hyperimmune Globulin Injection Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Global Downstream Application Analysis
5.1 Global Hyperimmune Globulin Injection Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Hyperimmune Globulin Injection Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Hyperimmune Globulin Injection Sales and Revenue by Type (2020-2031)
6.4 North America Hyperimmune Globulin Injection Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Hyperimmune Globulin Injection Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Hyperimmune Globulin Injection Sales and Revenue by Type (2020-2031)
7.4 Europe Hyperimmune Globulin Injection Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Hyperimmune Globulin Injection Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Hyperimmune Globulin Injection Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Hyperimmune Globulin Injection Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Hyperimmune Globulin Injection Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Hyperimmune Globulin Injection Sales and Revenue by Type (2020-2031)
9.4 Central and South America Hyperimmune Globulin Injection Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Hyperimmune Globulin Injection Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Hyperimmune Globulin Injection Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Hyperimmune Globulin Injection Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Hyperimmune Globulin Injection Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa

11 Corporate Profile
11.1 CSL Behring
11.1.1 CSL Behring Corporation Information
11.1.2 CSL Behring Business Overview
11.1.3 CSL Behring Hyperimmune Globulin Injection Product Models, Descriptions and Specifications
11.1.4 CSL Behring Hyperimmune Globulin Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 CSL Behring Hyperimmune Globulin Injection Sales by Product in 2024
11.1.6 CSL Behring Hyperimmune Globulin Injection Sales by Application in 2024
11.1.7 CSL Behring Hyperimmune Globulin Injection Sales by Geographic Area in 2024
11.1.8 CSL Behring Hyperimmune Globulin Injection SWOT Analysis
11.1.9 CSL Behring Recent Developments
11.2 Grifols
11.2.1 Grifols Corporation Information
11.2.2 Grifols Business Overview
11.2.3 Grifols Hyperimmune Globulin Injection Product Models, Descriptions and Specifications
11.2.4 Grifols Hyperimmune Globulin Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Grifols Hyperimmune Globulin Injection Sales by Product in 2024
11.2.6 Grifols Hyperimmune Globulin Injection Sales by Application in 2024
11.2.7 Grifols Hyperimmune Globulin Injection Sales by Geographic Area in 2024
11.2.8 Grifols Hyperimmune Globulin Injection SWOT Analysis
11.2.9 Grifols Recent Developments
11.3 Biotest
11.3.1 Biotest Corporation Information
11.3.2 Biotest Business Overview
11.3.3 Biotest Hyperimmune Globulin Injection Product Models, Descriptions and Specifications
11.3.4 Biotest Hyperimmune Globulin Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Biotest Hyperimmune Globulin Injection Sales by Product in 2024
11.3.6 Biotest Hyperimmune Globulin Injection Sales by Application in 2024
11.3.7 Biotest Hyperimmune Globulin Injection Sales by Geographic Area in 2024
11.3.8 Biotest Hyperimmune Globulin Injection SWOT Analysis
11.3.9 Biotest Recent Developments
11.4 Kedrion
11.4.1 Kedrion Corporation Information
11.4.2 Kedrion Business Overview
11.4.3 Kedrion Hyperimmune Globulin Injection Product Models, Descriptions and Specifications
11.4.4 Kedrion Hyperimmune Globulin Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Kedrion Hyperimmune Globulin Injection Sales by Product in 2024
11.4.6 Kedrion Hyperimmune Globulin Injection Sales by Application in 2024
11.4.7 Kedrion Hyperimmune Globulin Injection Sales by Geographic Area in 2024
11.4.8 Kedrion Hyperimmune Globulin Injection SWOT Analysis
11.4.9 Kedrion Recent Developments
11.5 Emergent
11.5.1 Emergent Corporation Information
11.5.2 Emergent Business Overview
11.5.3 Emergent Hyperimmune Globulin Injection Product Models, Descriptions and Specifications
11.5.4 Emergent Hyperimmune Globulin Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Emergent Hyperimmune Globulin Injection Sales by Product in 2024
11.5.6 Emergent Hyperimmune Globulin Injection Sales by Application in 2024
11.5.7 Emergent Hyperimmune Globulin Injection Sales by Geographic Area in 2024
11.5.8 Emergent Hyperimmune Globulin Injection SWOT Analysis
11.5.9 Emergent Recent Developments
11.6 Kamada
11.6.1 Kamada Corporation Information
11.6.2 Kamada Business Overview
11.6.3 Kamada Hyperimmune Globulin Injection Product Models, Descriptions and Specifications
11.6.4 Kamada Hyperimmune Globulin Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Kamada Recent Developments
11.7 CNBG
11.7.1 CNBG Corporation Information
11.7.2 CNBG Business Overview
11.7.3 CNBG Hyperimmune Globulin Injection Product Models, Descriptions and Specifications
11.7.4 CNBG Hyperimmune Globulin Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 CNBG Recent Developments
11.8 Hualan Bio
11.8.1 Hualan Bio Corporation Information
11.8.2 Hualan Bio Business Overview
11.8.3 Hualan Bio Hyperimmune Globulin Injection Product Models, Descriptions and Specifications
11.8.4 Hualan Bio Hyperimmune Globulin Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Hualan Bio Recent Developments
11.9 Shanghai RAAS
11.9.1 Shanghai RAAS Corporation Information
11.9.2 Shanghai RAAS Business Overview
11.9.3 Shanghai RAAS Hyperimmune Globulin Injection Product Models, Descriptions and Specifications
11.9.4 Shanghai RAAS Hyperimmune Globulin Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Shanghai RAAS Recent Developments
11.10 CBPO
11.10.1 CBPO Corporation Information
11.10.2 CBPO Business Overview
11.10.3 CBPO Hyperimmune Globulin Injection Product Models, Descriptions and Specifications
11.10.4 CBPO Hyperimmune Globulin Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 CBPO Recent Developments
11.11 Sichuan Yuanda Shuyang
11.11.1 Sichuan Yuanda Shuyang Corporation Information
11.11.2 Sichuan Yuanda Shuyang Business Overview
11.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Product Models, Descriptions and Specifications
11.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Sichuan Yuanda Shuyang Recent Developments
11.12 ADMA Biologics
11.12.1 ADMA Biologics Corporation Information
11.12.2 ADMA Biologics Business Overview
11.12.3 ADMA Biologics Hyperimmune Globulin Injection Product Models, Descriptions and Specifications
11.12.4 ADMA Biologics Hyperimmune Globulin Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 ADMA Biologics Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Hyperimmune Globulin Injection Industry Chain
12.2 Hyperimmune Globulin Injection Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Hyperimmune Globulin Injection Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Hyperimmune Globulin Injection Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Hyperimmune Globulin Injection Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Hyperimmune Globulin Injection Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

Table of Figures

List of Tables
 Table 1. Global Hyperimmune Globulin Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Hyperimmune Globulin Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Hyperimmune Globulin Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Hyperimmune Globulin Injection Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Hyperimmune Globulin Injection Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Hyperimmune Globulin Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Hyperimmune Globulin Injection Sales by Region (2020-2025) & (K Units)
 Table 8. Global Hyperimmune Globulin Injection Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Hyperimmune Globulin Injection Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Hyperimmune Globulin Injection Sales Share by Manufacturers (2020-2025)
 Table 12. Global Hyperimmune Globulin Injection Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Hyperimmune Globulin Injection Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Hyperimmune Globulin Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperimmune Globulin Injection as of 2024)
 Table 16. Global Hyperimmune Globulin Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Hyperimmune Globulin Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Hyperimmune Globulin Injection Manufacturing Base and Headquarters
 Table 19. Global Hyperimmune Globulin Injection Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Hyperimmune Globulin Injection Sales by Type (2020-2025) & (K Units)
 Table 23. Global Hyperimmune Globulin Injection Sales by Type (2026-2031) & (K Units)
 Table 24. Global Hyperimmune Globulin Injection Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Hyperimmune Globulin Injection Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Hyperimmune Globulin Injection ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Hyperimmune Globulin Injection Sales by Application (2020-2025) & (K Units)
 Table 29. Global Hyperimmune Globulin Injection Sales by Application (2026-2031) & (K Units)
 Table 30. Hyperimmune Globulin Injection High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Hyperimmune Globulin Injection Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Hyperimmune Globulin Injection Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Hyperimmune Globulin Injection ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Hyperimmune Globulin Injection Growth Accelerators and Market Barriers
 Table 37. North America Hyperimmune Globulin Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Hyperimmune Globulin Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Hyperimmune Globulin Injection Growth Accelerators and Market Barriers
 Table 40. Europe Hyperimmune Globulin Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Hyperimmune Globulin Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Hyperimmune Globulin Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Hyperimmune Globulin Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Hyperimmune Globulin Injection Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Hyperimmune Globulin Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Hyperimmune Globulin Injection Investment Opportunities and Key Challenges
 Table 47. Central and South America Hyperimmune Globulin Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Hyperimmune Globulin Injection Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Hyperimmune Globulin Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. CSL Behring Corporation Information
 Table 51. CSL Behring Description and Major Businesses
 Table 52. CSL Behring Product Models, Descriptions and Specifications
 Table 53. CSL Behring Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. CSL Behring Sales Value Proportion by Product in 2024
 Table 55. CSL Behring Sales Value Proportion by Application in 2024
 Table 56. CSL Behring Sales Value Proportion by Geographic Area in 2024
 Table 57. CSL Behring Hyperimmune Globulin Injection SWOT Analysis
 Table 58. CSL Behring Recent Developments
 Table 59. Grifols Corporation Information
 Table 60. Grifols Description and Major Businesses
 Table 61. Grifols Product Models, Descriptions and Specifications
 Table 62. Grifols Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Grifols Sales Value Proportion by Product in 2024
 Table 64. Grifols Sales Value Proportion by Application in 2024
 Table 65. Grifols Sales Value Proportion by Geographic Area in 2024
 Table 66. Grifols Hyperimmune Globulin Injection SWOT Analysis
 Table 67. Grifols Recent Developments
 Table 68. Biotest Corporation Information
 Table 69. Biotest Description and Major Businesses
 Table 70. Biotest Product Models, Descriptions and Specifications
 Table 71. Biotest Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Biotest Sales Value Proportion by Product in 2024
 Table 73. Biotest Sales Value Proportion by Application in 2024
 Table 74. Biotest Sales Value Proportion by Geographic Area in 2024
 Table 75. Biotest Hyperimmune Globulin Injection SWOT Analysis
 Table 76. Biotest Recent Developments
 Table 77. Kedrion Corporation Information
 Table 78. Kedrion Description and Major Businesses
 Table 79. Kedrion Product Models, Descriptions and Specifications
 Table 80. Kedrion Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. Kedrion Sales Value Proportion by Product in 2024
 Table 82. Kedrion Sales Value Proportion by Application in 2024
 Table 83. Kedrion Sales Value Proportion by Geographic Area in 2024
 Table 84. Kedrion Hyperimmune Globulin Injection SWOT Analysis
 Table 85. Kedrion Recent Developments
 Table 86. Emergent Corporation Information
 Table 87. Emergent Description and Major Businesses
 Table 88. Emergent Product Models, Descriptions and Specifications
 Table 89. Emergent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Emergent Sales Value Proportion by Product in 2024
 Table 91. Emergent Sales Value Proportion by Application in 2024
 Table 92. Emergent Sales Value Proportion by Geographic Area in 2024
 Table 93. Emergent Hyperimmune Globulin Injection SWOT Analysis
 Table 94. Emergent Recent Developments
 Table 95. Kamada Corporation Information
 Table 96. Kamada Description and Major Businesses
 Table 97. Kamada Product Models, Descriptions and Specifications
 Table 98. Kamada Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. Kamada Recent Developments
 Table 100. CNBG Corporation Information
 Table 101. CNBG Description and Major Businesses
 Table 102. CNBG Product Models, Descriptions and Specifications
 Table 103. CNBG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 104. CNBG Recent Developments
 Table 105. Hualan Bio Corporation Information
 Table 106. Hualan Bio Description and Major Businesses
 Table 107. Hualan Bio Product Models, Descriptions and Specifications
 Table 108. Hualan Bio Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 109. Hualan Bio Recent Developments
 Table 110. Shanghai RAAS Corporation Information
 Table 111. Shanghai RAAS Description and Major Businesses
 Table 112. Shanghai RAAS Product Models, Descriptions and Specifications
 Table 113. Shanghai RAAS Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 114. Shanghai RAAS Recent Developments
 Table 115. CBPO Corporation Information
 Table 116. CBPO Description and Major Businesses
 Table 117. CBPO Product Models, Descriptions and Specifications
 Table 118. CBPO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 119. CBPO Recent Developments
 Table 120. Sichuan Yuanda Shuyang Corporation Information
 Table 121. Sichuan Yuanda Shuyang Description and Major Businesses
 Table 122. Sichuan Yuanda Shuyang Product Models, Descriptions and Specifications
 Table 123. Sichuan Yuanda Shuyang Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 124. Sichuan Yuanda Shuyang Recent Developments
 Table 125. ADMA Biologics Corporation Information
 Table 126. ADMA Biologics Description and Major Businesses
 Table 127. ADMA Biologics Product Models, Descriptions and Specifications
 Table 128. ADMA Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 129. ADMA Biologics Recent Developments
 Table 130. Key Raw Materials Distribution
 Table 131. Raw Materials Key Suppliers
 Table 132. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 133. Milestones in Production Technology Evolution
 Table 134. Distributors List
 Table 135. Market Trends and Market Evolution
 Table 136. Market Drivers and Opportunities
 Table 137. Market Challenges, Risks, and Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources


List of Figures
 Figure 1. Hyperimmune Globulin Injection Product Picture
 Figure 2. Global Hyperimmune Globulin Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Hepatitis B Immuneglobulins Product Picture
 Figure 4. Rabies Immuneglobulins Product Picture
 Figure 5. Tetanus Toxin Immuneglobulins Product Picture
 Figure 6. Rho(D) Immune Globulin Product Picture
 Figure 7. Cytomegalovirus Immune Globulin Product Picture
 Figure 8. Varicella-Zoster Immune Globulin Product Picture
 Figure 9. Others Product Picture
 Figure 10. Global Hyperimmune Globulin Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 11. Government Institution
 Figure 12. Private Sector
 Figure 13. Others
 Figure 14. Hyperimmune Globulin Injection Report Years Considered
 Figure 15. Global Hyperimmune Globulin Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 17. Global Hyperimmune Globulin Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 18. Global Hyperimmune Globulin Injection Revenue Market Share by Region (2020-2031)
 Figure 19. Global Hyperimmune Globulin Injection Sales (2020-2031) & (K Units)
 Figure 20. Global Hyperimmune Globulin Injection Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 21. Global Hyperimmune Globulin Injection Sales Market Share by Region (2020-2031)
 Figure 22. Top 5 and Top 10 Manufacturers Hyperimmune Globulin Injection Sales Volume Market Share in 2024
 Figure 23. Global Hyperimmune Globulin Injection Revenue Market Share Ranking (2024)
 Figure 24. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 25. Hepatitis B Immuneglobulins Revenue Market Share by Manufacturer in 2024
 Figure 26. Rabies Immuneglobulins Revenue Market Share by Manufacturer in 2024
 Figure 27. Tetanus Toxin Immuneglobulins Revenue Market Share by Manufacturer in 2024
 Figure 28. Rho(D) Immune Globulin Revenue Market Share by Manufacturer in 2024
 Figure 29. Cytomegalovirus Immune Globulin Revenue Market Share by Manufacturer in 2024
 Figure 30. Varicella-Zoster Immune Globulin Revenue Market Share by Manufacturer in 2024
 Figure 31. Others Revenue Market Share by Manufacturer in 2024
 Figure 32. Global Hyperimmune Globulin Injection Sales Market Share by Type (2020-2031)
 Figure 33. Global Hyperimmune Globulin Injection Revenue Market Share by Type (2020-2031)
 Figure 34. Global Hyperimmune Globulin Injection Sales Market Share by Application (2020-2031)
 Figure 35. Global Hyperimmune Globulin Injection Revenue Market Share by Application (2020-2031)
 Figure 36. North America Hyperimmune Globulin Injection Sales YoY (2020-2031) & (K Units)
 Figure 37. North America Hyperimmune Globulin Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 38. North America Top 5 Manufacturers Hyperimmune Globulin Injection Sales Revenue (US$ Million) in 2024
 Figure 39. North America Hyperimmune Globulin Injection Sales Volume (K Units) by Type (2020- 2031)
 Figure 40. North America Hyperimmune Globulin Injection Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 41. North America Hyperimmune Globulin Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 42. North America Hyperimmune Globulin Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 43. US Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 44. Canada Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 45. Mexico Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 46. Europe Hyperimmune Globulin Injection Sales YoY (2020-2031) & (K Units)
 Figure 47. Europe Hyperimmune Globulin Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 48. Europe Top 5 Manufacturers Hyperimmune Globulin Injection Sales Revenue (US$ Million) in 2024
 Figure 49. Europe Hyperimmune Globulin Injection Sales Volume (K Units) by Type (2020-2031)
 Figure 50. Europe Hyperimmune Globulin Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 51. Europe Hyperimmune Globulin Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 52. Europe Hyperimmune Globulin Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 53. Germany Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 54. France Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 55. U.K. Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 56. Italy Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 57. Russia Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 58. Asia-Pacific Hyperimmune Globulin Injection Sales YoY (2020-2031) & (K Units)
 Figure 59. Asia-Pacific Hyperimmune Globulin Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 60. Asia-Pacific Top 8 Manufacturers Hyperimmune Globulin Injection Sales Revenue (US$ Million) in 2024
 Figure 61. Asia-Pacific Hyperimmune Globulin Injection Sales Volume (K Units) by Type (2020- 2031)
 Figure 62. Asia-Pacific Hyperimmune Globulin Injection Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 63. Asia-Pacific Hyperimmune Globulin Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 64. Asia-Pacific Hyperimmune Globulin Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 65. Indonesia Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 66. Japan Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 67. South Korea Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 68. China Taiwan Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 69. India Hyperimmune Globulin Injection Revenue (2020-2031) & (US$ Million)
 Figure 70. Central and South America Hyperimmune Globulin Injection Sales YoY (2020-2031) & (K Units)
 Figure 71. Central and South America Hyperimmune Globulin Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 72. Central and South America Top 5 Manufacturers Hyperimmune Globulin Injection Sales Revenue (US$ Million) in 2024
 Figure 73. Central and South America Hyperimmune Globulin Injection Sales Volume (K Units) by Type (2021-2031)
 Figure 74. Central and South America Hyperimmune Globulin Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 75. Central and South America Hyperimmune Globulin Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 76. Central and South America Hyperimmune Globulin Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 77. Brazil Hyperimmune Globulin Injection Revenue (2020-2025) & (US$ Million)
 Figure 78. Argentina Hyperimmune Globulin Injection Revenue (2020-2025) & (US$ Million)
 Figure 79. Middle East, and Africa Hyperimmune Globulin Injection Sales YoY (2020-2031) & (K Units)
 Figure 80. Middle East and Africa Hyperimmune Globulin Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 81. Middle East and Africa Top 5 Manufacturers Hyperimmune Globulin Injection Sales Revenue (US$ Million) in 2024
 Figure 82. Middle East and Africa Hyperimmune Globulin Injection Sales Volume (K Units) by Type (2021-2031)
 Figure 83. South America Hyperimmune Globulin Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 84. Middle East and Africa Hyperimmune Globulin Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 85. Middle East and Africa Hyperimmune Globulin Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 86. GCC Countries Hyperimmune Globulin Injection Revenue (2020-2025) & (US$ Million)
 Figure 87. Turkey Hyperimmune Globulin Injection Revenue (2020-2025) & (US$ Million)
 Figure 88. Egypt Hyperimmune Globulin Injection Revenue (2020-2025) & (US$ Million)
 Figure 89. South Africa Hyperimmune Globulin Injection Revenue (2020-2025) & (US$ Million)
 Figure 90. Hyperimmune Globulin Injection Industry Chain Mapping
 Figure 91. Regional Hyperimmune Globulin Injection Manufacturing Base Distribution (%)
 Figure 92. Global Hyperimmune Globulin Injection Production Market Share by Region (2020-2031)
 Figure 93. Hyperimmune Globulin Injection Production Process
 Figure 94. Regional Hyperimmune Globulin Injection Production Cost Structure
 Figure 95. Channels of Distribution (Direct Vs Distribution)
 Figure 96. Bottom-up and Top-down Approaches for This Report
 Figure 97. Data Triangulation
 Figure 98. Key Executives Interviewed

以下、関連資料のご紹介